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Aims: Medullary breast cancer (MBC) is a biologically
distinct subtype of breast cancer characterized by
prominent lymphocytic inﬁltrates and a favourable
clinical outcome. Tumour-inﬁltrating CD8+ effector T
cells may contribute to the good prognosis of this type
of cancer; however, certain subtypes of lymphocyte,
such as FoxP3+ regulatory T cells (Tregs), can also
suppress antitumour immunity.
Methods and results: We determined tumour inﬁltra-
tion by FoxP3+, CCL22+ and CD8+ cells in parafﬁn-
embedded sections of MBC, and, as a reference, in
samples of grade 3 ductal, lobular and mucinous breast
cancer. All analysed MBCs were strongly inﬁltrated by
FoxP3+ cells, whereas only weak inﬁltrates were
detected in ductal or lobular breast cancer. This ﬁnding
was unexpected, given the good prognosis of MBC.
Strikingly, the number of CD8+ T cells exceeded the
number of FoxP3+ cells in MBC (ratio of CD8+ to
FoxP3+ cells of 2.6), whereas equal amounts of both
cell types were found in ductal breast cancer (ratio of
CD8+ to FoxP3+ cells of 1.1). In both types of breast
cancer, we also detected cells expressing the Treg-
attracting chemokine CCL22.
Conclusions: In breast cancer, a predominance of
tumour-inﬁltrating CD8+ over FoxP3+ cells was
observed in MBC. Thus, the ratio of CD8+ to FoxP3+
cells rather than the absolute number of intratumoral
FoxP3+ cells may be predictive for the clinical outcome
of cancer.
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Introduction
Medullary breast cancer (MBC) is a particularly inter-
esting subtype, as it is characterized by less frequent
lymph node metastasis1 and good clinical outcome.2
Histologically, it consists of large sheets of poorly
differentiated tumour cells appearing in a syncytial
growth pattern and prominent lymphocytic inﬁltration
of the tumour stroma.3 Several authors have suggested
that a high number of tumour-inﬁltrating lymphocytes
may help to limit tumour burden and thus contribute
to good prognosis in MBC.3–6 Tumour-inﬁltrating
lymphocytes, however, represent a heterogeneous
group of immune cells composed of both effector cell
subsets and immunosuppressive cells.
Regulatory T cells (Tregs) represent a population of
immunosuppressive cells that are capable of inhibiting
both innate and adaptive immunity. A key function of
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Tregs is the suppression of immune responses directed
against self-antigens, and these cells are therefore
crucial for the prevention of autoimmunity.7 However,
Tregs also inhibit the cytotoxic activity of CD8+ T cells
against malignant tumours, and many studies have
shown that Tregs play a crucial role in tumour-induced
immunosuppression.8 The transcription factor FoxP3 is,
so far, the most speciﬁc marker for the identiﬁcation of
human Tregs, although it can also be expressed by other
lymphocytes upon activation.9 Inﬁltration of tumours
by FoxP3+ Tregs has been observed in different types of
human cancer, and is associated with poor progno-
sis.10,11 The recruitment of Tregs to the tumour tissue
depends on speciﬁc mediators that attract these cells to
the tumour site. The chemokine CCL22 represents one
important factor12 that can mediate migration of
FoxP3+ Tregs to the tumour site.10
Although a high number of intratumoral lympho-
cytes is consistently seen in MBC, inﬁltration by FoxP3+
Tregs in this type of breast cancer has not been
investigated. In this study, we analysed parafﬁn-embed-
ded material of 13 MBCs, 34 ductal breast cancers
(DBCs) and seven lobular or mucinous breast cancers for
the presence of FoxP3+ and CD8+ lymphocytes and for
CCL22+ cells in the tumour tissue. Interestingly, all
analysedMBCs were strongly inﬁltrated by both FoxP3+
and CD8+ cells. CCL22 was detected in all tumours, and
was mainly expressed by tumour-inﬁltrating immune
cells and, in a few cases, by the cancer cells themselves.
We further determined the ratio of effector T cells to
Tregs in the tumours, and found that the number of
intratumoral CD8+ cells clearly exceeded the number of
FoxP3+ cells in MBCs but not in DBCs. The high ratio of
CD8+ to FoxP3+ cells may thus contribute to the
relatively good prognosis of patients with MBC.
Materials and methods
patients
Parafﬁn-embeddedmaterial of 54 breast cancer patients,
including 13MBCs, 34 DBCs, four lobular breast cancers
and three mucinous carcinomas, was used for histolog-
ical analysis (Table 1). All cases were retrieved from the
archives of the Institute of Pathology of the Ludwig
Maximilian University, Munich, Germany. The age of
the patients ranged from 26 to 80 years. All patients
were treated surgically between 2004 and 2008 at the
same institution (Department of Obstetrics and Gynae-
cology Maistrasse, University of Munich). Tumour
typing and staging were performed according to the
classiﬁcation of the International Union against Cancer.
MBC was diagnosed when the following ﬁve features
were present: (i) well-circumscribed tumour borders; (ii)
lymphocytic reaction diffusely in the tumour and in the
periphery; (iii) syncytial pattern of tumour cell growth;
(iv) high nuclear grade; and (v) highmitotic activity. The
DBC tissues used in this study were all grade 3. Tissue
sections were reviewed by independent investigators at
the Institute of Pathology of the Ludwig Maximilian
University, Munich.
immunohistology
All parafﬁn-embedded specimens were cut at 2–3 lm
and mounted on SuperFrost Plus microscope slides
(Menzel Gla¨ser, Braunschweig, Germany). After depa-
rafﬁnization and rehydration, immunohistochemical
assays were performed with standard methods. The
following antibodies were used: mouse anti-human
FoxP3 (1:100; Abcam, Cambridge, UK), rabbit anti-
human CCL22 (1:350; Peprotech, Rocky Hill, NJ,
USA), and rabbit anti-human CD8 (1:50; Thermo
Fisher Scientiﬁc, Fremont, CA, USA). Appropriate
horseradish peroxidase-conjugated and alkaline phos-
phatase-conjugated secondary antibodies were used for
detection. The amounts of tumour-inﬁltrating FoxP3+,
CCL22+ and CD8+ cells were evaluated semiquantita-
tively by analysing the complete surface of the tissue
section. The following scoring system was used: ), no
inﬁltrating cells; +, low numbers of inﬁltrating cells;
++, medium numbers of inﬁltrating cells; and +++,
high numbers of inﬁltrating cells. For analysis of the
ratio of CD8+ to FoxP3+ cells, absolute cell numbers
inﬁltrating the tumour epithelium were counted in
digital images derived from CD8-stained and FoxP3-
stained serial sections, and the ratio was calculated for
each pair. Digital images were obtained at 20-fold or
40-fold magniﬁcation (Axiovert Inverse Microscope;
Carl Zeiss, Jena, Germany), and processed with Adobe
Photoshop for adjustment of contrast and size.
cell culture and enzyme-l inked
immunosorbent assay (el isa)
The human breast cancer cell lines MCF7 and MDA-
MB-231 were maintained in Dulbecco’s modiﬁed
Eagle’s medium supplemented with 10% fetal bovine
serum, 1% l-glutamine, 1 U ⁄ ml penicillin, and
0.1 mg ⁄ ml streptomycin (all PAA Laboratories, Coel-
be, Germany). Dendritic cells were generated by using
peripheral blood mononuclear cells from peripheral
blood of healthy donors and by culturing the adherent
fraction in the presence of granulocyte–macrophage
colony-stimulating factor (1000 U ⁄ ml) and interleu-
kin-4 (500 U ⁄ ml) for 24 h. Supernatants were assayed
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for CCL22 by ELISA (R&D Systems, Minneapolis, MN,
USA). For immunocytology, single-cell suspensions of
formalin-ﬁxed cells were embedded in parafﬁn and
stained as described.
statist ical analysis
Data are presented as means in bar diagrams or as box
plots, and were analysed with unpaired Student’s t-test.
Statistical analysis was performed with Graphpad Prism
software.
Results
mbc is strongly infiltrated by foxp3+ cells
To determine Treg inﬁltration in the tumour tissue of
patients with MBC, we stained FoxP3+ cells in
parafﬁn-embedded material of 13 individuals and then
performed semiquantitative evaluation of the inﬁltra-
tion density. Interestingly, all analysed MBCs were
strongly inﬁltrated by FoxP3+ cells (Figure 1A). All of
these cells showed the typical nuclear staining pattern
of the Treg-associated transcription factor FoxP3. In
contrast, only a few DBCs were inﬁltrated by FoxP3+
cells, with 30 of 34 analysed tumours containing no or
low amounts of cells. Low numbers of FoxP3+ cells
were also observed in the four lobular breast cancers
and the three mucinous carcinomas. In all breast
cancer tissues, two different types of inﬁltration by
FoxP3+ cells were observed: ﬁrst, inﬁltration into the
tumour epithelium with direct contact with cancer
cells (Figure 1B); and second, the presence of FoxP3+
cells in the tumour stroma or in lymphoid clusters that
were located either in or around the tumour tissue.
Both patterns were observed in MBCs and DBCs, but
Table 1. Patient and tumour characteristics
Histological subtype
Medullary Invasive ductal Lobular Mucinous
Number of samples 13 34 4 3
Age in years (range) 49.7 (32–71) 54.4 (26–80) 53.0 (41–73) 65.3 (58–78)
TNM stage
T1 3 9 1 1
T2 9 13 3 1
T3 1 8 0 1
T4 0 4 0 0
N0 8 12 1 1
N1 4 12 1 1
N2 0 7 1 0
N3 0 3 1 0
Nx 1 0 0 1
M1 0 17 0 0
Mx 13 17 4 3
HER-2 ⁄ neu+ 3 21 0 0
Tumour grade (SBR)
2 1 0 4 3
3 12 34 0 0
SBR, Scarff-Bloom-Richardson Classiﬁcation
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lymphoid clusters were more frequent in MBCs. In
contrast to the tumour area, FoxP3+ cells were almost
absent from the adjacent healthy breast tissue (Fig-
ure 1C). In conclusion, MBCs are inﬁltrated by high
numbers of FoxP3+ cells, whereas other subtypes of
breast cancer contain few of these immunosuppressive
cells.
the treg-attracting chemokine ccl22 is
expressed by tumour-infiltrating immune
cells
Recruitment of Tregs to malignant tumours can be
mediated through the chemokine CCL22.10 To deter-
mine whether CCL22 may play a role in the migration
of Tregs to MBC, we analysed the expression of this
chemokine in the respective tumour tissues. CCL22
was mainly expressed by myeloid-shaped immune cells
that inﬁltrated both the tumour stroma and epithelium
(Figure 2A). CCL22+ immune cells were detected in all
tumours and the adjacent normal breast tissue, and no
difference in the frequency of these cells was observed
between MBCs and DBCs (Figure 2B). All of the four
lobular breast cancer tissues contained numerous
CCL22+ cells. In some, but not all, cases, CCL22+ cells
were locally associated with accumulations of FoxP3+
cells (Figure 2A). In addition to the expression by
immune cells, CCL22 was found to be also expressed by
the cancer cells (Figure 3A). Whereas almost none of
these cells were found in MBCs or lobular breast
cancers, CCL22 expression by cancer cells was detected
in 24% of DBCs (eight of 34). Generally, CCL22+
cancer cells were not found in local association with
FoxP3+ Tregs. In some tumours, CCL22 was also
strongly expressed by those cancer cells that inﬁltrated
lymphatic vessels (lymphoangiosis carcinomatosis; Fig-
ure 3A). In contrast, no CCL22 secretion was detected
in vitro from breast cancer cell lines (Figure 3B). In
B MBC
DBC
FoxP3 red CCL22 brown
C Normal breast
Density of infiltration by Foxp3+ cells: 
80
A
60
40
20
0
MBC
(n = 13)
DBC
(n = 34)
0
– + ++ +++
0 5 8
P < 0.0001
7 23 2 2
Pe
rc
e
n
ta
ge
o
f p
at
ie
nt
s
Figure 1. Breast cancer inﬁltration by FoxP3+ cells. Tumour-
inﬁltrating FoxP3+ lymphocytes were quantiﬁed in parafﬁn-embed-
ded samples of human breast cancer that were double-stained with
anti-human FoxP3 (red) and anti-human CCL22 (brown). A,
Inﬁltration by FoxP3+ cells was assessed semiquantitatively in
medullary breast cancer (MBC, black bars, n = 13) and ductal breast
cancer (DBC, white bars, n = 34) specimens (), no inﬁltration; +, low
inﬁltration; ++, high inﬁltration; +++, very high inﬁltration). Bars
indicate the percentage, and the numbers below indicate the absolute
number of tumour specimens. B,C, Representative examples of
inﬁltration by FoxP3+ cells are shown for (B) the tumour epithelium
of MBC and DBC, and for (C) the adjacent healthy breast tissue (·40
magniﬁcation).
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summary, CCL22+ immune cells were present in all
analysed breast cancer specimens, whereas expression
of this chemokine by cancer cells was less frequent and
limited to DBCs.
the number of cd8+ t cells exceeds the number
of tumour-infiltrating foxp3+ cells in mbc
The high levels of tumour-inﬁltrating FoxP3+ cells in
MBCs contrast with the relatively good prognosis of this
cancer. It is generally accepted that tumour-inﬁltrating
effector T cells, in contrast to Tregs, are associated with
a favourable outcome.13,14 We therefore analysed the
MBC tissues for the presence of CD8+ effector T cells,
and correlated these numbers with the inﬁltration by
FoxP3+ lymphocytes. We detected prominent inﬁltra-
tion of CD8+ T cells in all MBCs (Figure 4A), which is
in agreement with previous reports.6,15 In contrast,
most DBCs and all lobular breast cancers or mucinous
carcinomas were inﬁltrated only weakly by CD8+ cells.
In all tumours, CD8+ T cells were located not only in
the tumour epithelium but also in the stroma and in
lymphoid clusters. To determine the relationship of
CD8+ to FoxP3+ cells, we analysed serial sections of
either CD8-stained or FoxP3-stained MBC tissues.
Interestingly, we found important differences in the
ratio of CD8+ to FoxP3+ cells according to the
positions of both cell types in the tumour: in the
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Figure 2. Breast cancer inﬁltration by CCL22+ immune cells. A, Parafﬁn-embedded samples of human breast cancer were stained as in Figure 1,
and representative examples for CCL22+ immune cells (brown) are shown for medullary breast cancer (MBC), ductal breast cancer (DBC),
and adjacent normal breast tissue (·40 magniﬁcation). B, Inﬁltration by CCL22+ myeloid-shaped cells was assessed semiquantitatively for
MBC (n = 13, black bars), DBC (n = 34, white bars), and lobular breast cancer (LBC, n = 4, grey bars) (quantiﬁcation score as in Figure 1).
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tumour epithelium of MBCs, we observed a striking
predominance of CD8+ T cells, whereas a variable ratio
of CD8+ to FoxP3+ cells was seen in lymphoid clusters
and the tumour stroma (Figure 4B). To quantify the
ratio of CD8+ to FoxP3+ cells in the tumour epithelium
of MBCs and DBCs, we counted the numbers of both
cell types in congruent visual ﬁelds, using serial
sections, and calculated the mean of all ratios for both
tumour subtypes (Figure 4C). Interestingly, a high
ratio of CD8+ to FoxP3+ cells was conﬁrmed in the
tumour epithelium of MBCs (mean ratio of CD8+ to
FoxP3+ cells of 2.6), whereas a signiﬁcantly lower ratio
was found in DBCs (mean ratio of CD8+ to FoxP3+
cells of 1.1). Thus, in contrast to DBCs, the number of
intratumoral CD8+ T cells in MBC clearly exceeds the
number of FoxP3+ cells.
Discussion
MBCs consistently feature prominent lymphocytic
inﬁltrates that are associated with good clinical out-
come.3 In general, grade 3 breast cancer with prom-
inent lymphocytic inﬁltration has been reported to
have a more favourable prognosis.16 We show here, for
the ﬁrst time, that MBCs are strongly inﬁltrated by
FoxP3+ cells, a population of lymphocytes with an
immunosuppressive function.7 High numbers of
FoxP3+ cells were observed in all analysed MBC
tissues, and both the tumour epithelium and the
surrounding stroma were inﬁltrated by these cells.
Although tumour inﬁltration by FoxP3+ cells has so
far not been investigated for MBCs, intratumoral Tregs
in DBC or lobular breast cancer have previously been
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Figure 3. Expression of CCL22 by breast cancer cells. A, Breast cancer samples were prepared as described in Figure 1. Expression of CCL22
by tumour cells (brown) is shown for examples of medullary breast cancer (MBC), ductal breast cancer (DBC) and lymphangiosis
carcinomatosis (lymphangiosis c.) within DBC. B, CCL22 was measured in the supernatants of two breast cancer cell lines by enzyme-linked
immunosorbent assay, and the supernatants of human dendritic cells were used as a positive control.
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Figure 4. Relationship of
tumour-inﬁltrating CD8+ to
FoxP3+ cells in breast cancer.
Serial sections of parafﬁn-
embedded breast cancer were
stained with either anti-human
CD8 (brown) or with anti-
human FoxP3 (red) together
with CCL22 (brown). A,
Inﬁltration by CD8+ cells was
assessed semiquantitatively for
medullary breast cancer (MBC)
(n = 13, black bars) and ductal
breast cancer (DBC) (n = 34,
white bars) specimens (quanti-
ﬁcation score as in Figure 1).
Bars indicate the percentage,
and the numbers below indicate
the absolute number of tumour
specimens. B, Congruent
microscopic ﬁelds demonstrate
the speciﬁc distribution of CD8+
and FoxP3+ cells in lymphoid
clusters (LC) and the tumour
epithelium (E) in tissue sections
of MBC. C, Intraepithelial CD8+
and FoxP3+ cells in MBC and
DBC were quantiﬁed in con-
gruent images of serial sections.
The mean ratios of CD8+ to
FoxP3+ cells and the ranges for
each type of tumour are shown
in a box plot.
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detected by histology,10,17–19 ﬂow cytometry,20 or
polymerase chain reaction (PCR).21,22 Two studies on
DBC, using tissue microarrays, have shown that the
number of tumour-inﬁltrating FoxP3+ cells is signiﬁ-
cantly correlated with reduced survival.11,23 One
recent study on invasive breast cancer, however, did
not ﬁnd a correlation between high Treg numbers and
survival, on the basis of multivariate analysis.24 The
ﬁndings in DBC are in line with studies on other types
of cancer, where the number of tumour-inﬁltrating
FoxP3+ cells is associated with poor prognosis.25,26
The strong inﬁltration of MBC by FoxP3+ cells and the
good prognosis of this tumour thus contrast with the
observations in other types of human cancer.
In addition to tumour-inﬁltrating FoxP3+ cells in
MBC, we detected high levels of intratumoral CD8+
cells. This is in agreement with previous reports that
have described tumour-inﬁltrating CD3+ and CD8+
cells in MBC.6,15 In contrast to Tregs, tumour
inﬁltration by T lymphocytes in general is thought
to positively inﬂuence the survival of cancer patients.
In a study on patients with ovarian cancer, the 5-year
survival rate was 38% among patients whose
tumours contained CD3+ cells versus 4.5% for
patients without intratumoral T cells.27 Similar ﬁnd-
ings, based on the examination of intratumoral T
cells, were observed for other types of cancer, such as
colorectal carcinoma and melanoma.28,29 In the
present study, MBCs were abundantly inﬁltrated by
both CD8+ and FoxP3+ cells, prompting us to
determine the ratio of these T-cell subpopulations.
Interestingly, we found a clear predominance of CD8+
T cells, reﬂected by a mean ratio of CD8+ to FoxP3+
cells of 2.6 in the tumour epithelium of MBCs. In
contrast, equal numbers of CD8+ and FoxP3+ cells
were found in the tumour epithelium of DBCs.
Although the mean ratio of CD8+ to FoxP3+ cells
showed a highly signiﬁcant difference between the
two types of breast cancer, there was some overlap, as
a few individual tumours did note show this pattern.
It would be interesting to analyse the clinical outcome
of these patients. DBC tissues in our study had
relatively low amounts of lymphocytic inﬁltrate, so it
would also be interesting to assess the ratio of CD8+
to FoxP3+ cells between MBCs and DBCs with
prominent inﬂammation. In summary, the high ratio
of intratumoral CD8+ to FoxP3+ cells could contrib-
ute to the good prognosis of MBC.
The recruitment of effector T cells or Tregs into
malignant tumours is generally mediated by speciﬁc
chemokines. CCR4 is a chemokine receptor that is
expressed at higher levels on CD4+ ⁄ FoxP3+ cells than
on other T-cell populations in human blood.12 One
ligand for CCR4 is CCL22, a chemokine that has been
detected in different human tumours.30,31 Indeed,
tumour homogenates can induce CCL22-dependent
migration of Tregs,32,33 and the role of CCL22 in the
recruitment of Tregs to tumours has also been demon-
strated in vivo.10 We investigated the expression of this
chemokine in different subtypes of breast cancer, and
found that all analysed tumours and, in addition, the
adjacent healthy breast tissues were inﬁltrated by
CCL22+ myeloid-shaped immune cells. These cells
were present in the tumour epithelium, the surround-
ing connective tissue and, in some cases, in lymphoid
clusters, where they were locally associated with
FoxP3+ Tregs. Unexpectedly, colocalization of
CCL22+ with FoxP3+ immune cells was generally
rare, and was limited to lymphoid accumulations.
Furthermore, no differences in the number of intratu-
moral CCL22+ cells were found between MBCs and
DBCs, although MBCs contained signiﬁcantly higher
numbers of FoxP3+ Tregs. In addition, no correlation
between the numbers of CCL22+ and FoxP3+ cells was
seen within the different DBC tissues analysed in this
study. This contrasts with a previous report based on
reverse-transcriptase PCR analysis that showed a
positive correlation between CCL22 and FoxP3 mRNA
transcripts in DBC.22 Another study on Tregs in DBC,
based on tissue microarrays, described a positive
correlation between CCL22 and FoxP3 expression in
lymphoid inﬁltrates but not in the tumour paren-
chyma, which is supported by our observations in
DBC.23 Thus, in breast cancer, CCL22+ immune cells
may attract FoxP3+ Tregs to lymphoid clusters sur-
rounding the tumour bed, but the functional role of
CCL22+ immune cells in the epithelium or the stroma
of the tumours remains unclear.
Although it has been hypothesized that intratumoral
CCL22 may be secreted not only by immune cells but
also by the tumour cells themselves, conclusive data
demonstrating CCL22 expression by cancer cells in
solid tumours have not been available so far. Here, we
have clearly shown that, in breast cancer, CCL22+
tumour cells do indeed exist. Whereas almost no
CCL22+ tumour cells were found in MBCs, we detected
these cells in eight of 34 DBC tissues. Interestingly, in
some of these tumours, cancer cells with strong CCL22
expression were found in lymphatic vessels, suggesting
that they might have a higher metastatic potential. As
CCL22+ cancer cells were not detected in association
with FoxP3+ or CD8+ cells, it remains questionable
whether these cells are involved in the recruitment of
lymphocytes. It will be interesting to ﬁnd out more
about the signiﬁcance of CCL22 expression by cancer
cells.
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In conclusion, our study shows that MBC, despite a
good clinical prognosis, is strongly inﬁltrated by
FoxP3+ cells. The number of intratumoral CD8+ cells
clearly exceeds the number of Tregs in most MBCs, but
not in other types of breast cancer. Thus, a predom-
inance of tumour-inﬁltrating CD8+ over FoxP3+ cells
is typically observed in the medullary subtype of breast
cancer, and may contribute to its favourable prognosis.
This supports the hypothesis that the ratio of intratu-
moral CD8+ to FoxP3+ cells rather than the absolute
number of Tregs is predictive for the clinical outcome of
cancer.
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